Current Trends in Systemic Therapies in Elderly Patients With Metastatic Colorectal Cancer
- 5 Downloads
Purpose of Review
The incidence of colorectal cancer increases with age and the population is aging, making treatment of elderly patients with metastatic colorectal cancer (mCRC) an increasingly common part of oncology practice. We review the literature regarding systemic treatment of colorectal cancer in the elderly population.
Most of the data for toxicity and efficacy of systemic therapies for mCRC in older patients comes from subgroup analysis of pooled phase II and III trials of both chemotherapy and targeted agents. These studies suggest that combination chemotherapy and targeted therapy are well-tolerated in fit elderly patients with slightly increased risk of toxicity.
Assessment of functional status independent of age can help differentiate which patients are candidates for combination chemotherapy, single-agent chemotherapy, targeted therapy, or supportive care. Fit, elderly patients should be treated as younger patients. Dose-reduced doublet therapy with dose escalation as tolerated is a safe and effective way to treat less-fit elderly patients. Most targeted therapies appear to be safe in the elderly population without significant concerns for increased toxicity.
KeywordsMetastatic colorectal cancer Elderly Targeted therapy Systemic therapy Comprehensive geriatric assessment
Compliance With Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2015/ (Accessed on February 21, 2019)
- 3.•• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients received chemotherapy: ASCO guidelines for geriatric oncology. J Clin Oncol. 2018;36:2326–47. https://doi.org/10.1200/JCO.2018.78.8687 Guidelines for utilizing the geriatric assessment to identify vulnerabilities not typically captured with traditional oncology assessments. CrossRefGoogle Scholar
- 4.Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, le Brun-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31:1464–70. https://doi.org/10.1200/JCO.2012.42.9894.CrossRefGoogle Scholar
- 6.Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open label, randomized factorial trial. Lancet. 2011;377:1749–59. https://doi.org/10.1016/S0140-6736(11)60399-1.CrossRefGoogle Scholar
- 7.Folprecht G, Cunningham D, Ross P, Glimelius B, di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–8. https://doi.org/10.1093/annonc.mdh344.CrossRefGoogle Scholar
- 9.Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91. https://doi.org/10.1200/JCO.2006.06.9039.CrossRefGoogle Scholar
- 10.Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009;70:134–44. https://doi.org/10.1016/j.critrevonc.2008.11.002.CrossRefGoogle Scholar
- 11.Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7:60–4. https://doi.org/10.3816/CCC.2008.n.009.CrossRefGoogle Scholar
- 12.Folprecht, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443–51. https://doi.org/10.1200/JCO.2007.14.0509.CrossRefGoogle Scholar
- 13.Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617–29. https://doi.org/10.1002/cncr.24305.CrossRefGoogle Scholar
- 15.•• Kerckhove N, Collin A, Conde A, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors or chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86. https://doi.org/10.3389/fphar.2017.00086 A comprehensive overview of the long-term effects of CIPN in cancer patients. CrossRefGoogle Scholar
- 17.Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9. https://doi.org/10.1200/JCO.2007.CrossRefGoogle Scholar
- 20.Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24:1574–9. https://doi.org/10.1093/annonc/mdt019.CrossRefGoogle Scholar
- 21.Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, et al. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018;29:133–8. https://doi.org/10.1093/annonc/mdx529.CrossRefGoogle Scholar
- 22.Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–85. https://doi.org/10.1016/S1470-2045(13)70154-2.CrossRefGoogle Scholar
- 23.Cutsem V, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;28:3499–506. https://doi.org/10.1200/JCO.2012.42.8201.CrossRefGoogle Scholar
- 24.Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;5:660–71. https://doi.org/10.1016/S1470-2045(15)70127-0.Google Scholar
- 27.Sastre J, Grávalos C, Rivera F, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist. 2012;17:339–45. https://doi.org/10.1634/theoncologist.2011-0406.CrossRefGoogle Scholar
- 28.Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64. https://doi.org/10.1200/JCO.2006.08.1620.CrossRefGoogle Scholar
- 29.Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, et al. Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist. 2015;20:1261–5. https://doi.org/10.1634/theoncologist.2015-0171.CrossRefGoogle Scholar
- 30.Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–7. https://doi.org/10.1200/JCO.2008.21.7828.CrossRefGoogle Scholar
- 31.•• Petrioli R, et al. Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:663–9. https://doi.org/10.1016/j.clcc.2018.07.002 Study demonstrating both efficacy and safety of CAPOX-bevacizumab followed by maintenance Cap and Bev in patients aged > 75 years with metastatic colorectal cancer. CrossRefGoogle Scholar